Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260815 | PMC |
| http://dx.doi.org/10.18632/oncotarget.252 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Illuminating the impact of CD38-induced adenosine formation in B-cell lymphoma.
Sci Rep
January 2025
Department of Clinical and Chemical Pathology, Ain shams University, Cairo, Egypt.
The expression of CD38 by cancer cells may mediate an immune-suppressive effect by producing Extracellular Adenosine (ADO) acting through G-protein-coupled cell surface receptors on cellular components and tumor cells. This can increase PD-1 expression and interaction with PD-L1, suppressing CD8 + cytotoxic T cells. This study examines the impact of heightened CD38 expression and extracellular ADO on various hematological and clinical parameters in patients with mature B-cell lymphoma, alongside their correlation with the soluble counterparts of the PD-1/PD-L1 axis.
View Article and Find Full Text PDFThe Role of microRNA-155 as a Biomarker in Diffuse Large B-Cell Lymphoma.
Biomedicines
November 2024
Department of Hematology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.
Diffuse Large B-cell Lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL). Despite the use of newer agents, such as polatuzumab vedotin, more than one-third of patients have ultimately relapsed or experienced refractory disease. MiRNAs are single-stranded, ~22-nucleotide-long RNAs that interact with their target RNA.
View Article and Find Full Text PDFAssessment of the diagnostic value of serum cathepsin S and its correlation with HDL subclasses in patients with non-Hodgkin's lymphoma.
J Med Biochem
September 2024
University of Belgrade, Faculty of Pharmacy, Department of Medical Biochemistry, Belgrade, Serbia.
Background: Recent findings point to the key role of cathepsin S (CTSS) in the survival of malignant cells, as well as the significance of the anti-apoptotic properties of high-density lipoprotein (HDL) that contribute to enhanced cell survival. The purpose of this study is to analyse CTSS as a potential biomarker in lymphoma. Also, in order to better understand the role of CTSS in the origin and development of lymphoma, its association with cystatin C (Cys C), lipids, and inflammatory markers was analysed.
View Article and Find Full Text PDFArticle Synopsis
- Plasma metabolomics analysis was conducted on 44 patients with relapsed/refractory B-cell non-Hodgkin lymphoma who were treated with CD19.CAR-T cell therapy, examining various time points before and after treatment.
- At pre-lymphodepletion, a specific metabolic profile indicated poor outcomes, with high levels of lipoproteins and lactate linked to elevated lactate dehydrogenase.
- By day 30, two patient clusters were identified: one group experienced long-term remission, while the other, with higher N-GlycA levels, was prone to relapse within a year, suggesting that pro-inflammatory shifts may be associated with relapse risk.
Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study.
J Hematol Oncol
December 2024
Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Background: Amulirafusp alfa (IMM0306) is a fusion protein of CD47 binding domain of signal-regulatory protein alpha (SIRPα) with CD20 monoclonal antibody on both heavy chains. This study aimed to evaluate the safety and preliminary efficacy of amulirafusp alfa in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL).
Methods: We enrolled patients with CD20 + r/r B-NHL who had previously received at least two lines of therapy to receive a single-dose of amulirafusp alfa in the first 2 weeks, followed by a multiple-dose period, in which the patients received the same intravenous dose every week in 4-week cycles.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!